Continuous measurement of cell growth as an optimal tool in drug toxicity testing (Supplement)
Award amount
$273,503Program and phase
STTR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EnTox Sciences LLC
- Proposal award date
- 2015-04-01
- Contract end date
- 2017-02-28
- UEI
- KKT9PGKVV2A1
- Solicitation number
- PA14-077
- Topic code
- NCATS
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Rapid Control and Assessment of Dissolved Gas Signals on Tissue Function andDisease.
- STTR Phase II: The BaroFuse, a Microfluidic Multichannel Measurement of Tissue Oxygen Consumption For Drug Testing
- STTR Phase I: The BaroFuse, a Microfluidic Multichannel Measurement of Tissue Oxygen Consumption For Drug Testing
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing
- A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production
- Development of CIL-0X: A Platform to Enhance Delivery of Inhaled RNA Therapeutics to Lung Cells
- Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells
- Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes
Research funding history
4 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $1,555,355. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation